Ascletis Pharma Inc. (HKG:1672)

Market Cap	12.52B +324.7%
Revenue (ttm)	2.59M -76.6%
Net Income	-283.33M
EPS	-0.29
Shares Out	986.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,137,000
Average Volume	2,409,855
Open	12.67
Previous Close	12.69
Day's Range	12.67 - 13.89
52-Week Range	3.76 - 18.75
Beta	0.51
RSI	45.76
Earnings Date	Mar 26, 2026

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 208
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1672

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY